APA Journals Spotlight Brain Stimulation, Esketamine and Precision Psychiatry in October Issues

The October 2026 issues of four American Psychiatric Association journals are now available online, and together they sketch a discipline in the middle of a technological and conceptual transition. The American Journal of Psychiatry, Psychiatric Services, American Journal of Psychotherapy, and Psychiatric Research and Clinical Practice each contribute a distinct layer to the picture, from device-based brain stimulation and artificial intelligence to health services research, psychotherapy delivery, and real-world pharmacotherapy comparisons. Taken as a whole, the new research reflects a growing conviction that psychiatric treatment is moving away from one-size-fits-all protocols and toward interventions tailored to individual brain circuits, life circumstances, and care settings.

The centerpiece of the October issue of The American Journal of Psychiatry is a special issue on neuromodulation and precision therapeutics, assembled with guest editor William McDonald, M.D., professor of psychiatry and behavioral sciences at Emory University School of Medicine. McDonald joins Ned Kalin, the journal’s editor-in-chief, on this month’s AJP Audio podcast to discuss the collection. The special issue arrives at a moment when neuromodulation, once a niche corner of psychiatry, has become one of its most active frontiers, encompassing transcranial magnetic stimulation, electroconvulsive therapy, vagus nerve stimulation, and emerging techniques that promise to steer electrical activity in deep brain circuits without surgery.

One of the issue’s framing contributions describes the current wave of brain stimulation therapeutic interventions in neuropsychiatry as a Cambrian explosion, an evocative metaphor borrowed from evolutionary biology to convey the sheer diversity of approaches now proliferating. Alongside it, a second perspective article examines artificial intelligence as the computational framework for adaptive closed-loop neuromodulation in psychiatry. Closed-loop systems, which sense neural activity and adjust stimulation parameters in real time, are widely viewed as the next step beyond fixed-protocol stimulation, and the article argues that machine learning provides the mathematical machinery needed to make such adaptive control clinically reliable.

The special issue also features original clinical trials that test whether precision targeting can improve outcomes. One randomized, sham-controlled trial investigates bilateral theta-burst stimulation of dorsolateral prefrontal cortex regions for late-life depression, a population in which treatment-resistant mood disorders carry substantial disability and medical burden. A companion study reports convergent network localization of brain stimulation targets for trait anxiety, an approach that uses converging evidence about brain networks to identify where stimulation might most effectively modulate a given symptom dimension. AJP Deputy Editor Daniel Pine, M.D., highlights both studies in accompanying videos for the journal’s readership.

Two further trials push the precision theme further. The first, the CORRECT-BD trial, compares clinical and cognitive outcomes of right unilateral ultrabrief electroconvulsive therapy against magnetic seizure therapy for bipolar depression, a comparison that speaks directly to a longstanding clinical concern: preserving cognition while retaining the robust antidepressant efficacy of seizure-based treatments. The second is an individualized, connectivity-guided versus conventional targeting trial of accelerated theta-burst stimulation in depression, a randomized, double-blind, parallel-design study that asks whether personalizing stimulation targets to each patient’s brain connectivity outperforms standard coordinate-based targeting.

The issue also revisits one of the most consequential and debated studies in the field. The RECOVER trial of vagus nerve stimulation in markedly treatment-resistant depression is examined in an article on its critical findings, lessons learned, and future directions, with lead author Charles R. Conway, M.D., discussing the results on the AJP Audio podcast. Additional contributions survey precision neuromodulation with a focus on temporal interference stimulation, a technique designed to reach deep brain structures noninvasively by interfering two high-frequency fields at a targeted point. A commentary argues for advancing brain stimulation toward first-line psychiatric therapy through wearable disposable electrotherapy, while another article addresses implantable neuromodulation devices in psychiatry, weighing human fidelity and the implementation challenges that stand between promising devices and routine clinical use.

The October issue of Psychiatric Services shifts the lens from circuits to systems, publishing research on how mental health care is organized, measured, and delivered. Highlights include the Mental Wellness Tool, a brief screener designed to detect mental disorders, substance use disorders, and suicide risk in a single instrument, and a set of recommendations from a participatory policymaking symposium on emergency psychiatric evaluation of people under arrest, an area where clinical practice, law enforcement, and civil rights intersect. Other articles examine VA health care utilization among U.S. veterans through the influence of social determinants of health, and a methodological piece on suicide surveillance and Simpson’s Paradox warns that aggregating data can obscure critical patterns that appear only when populations are disaggregated.

Access and equity questions recur throughout the issue. One study documents wait times and documentation requirements for child psychiatric care across payer and facility types, quantifying the administrative friction families face when seeking help for children. Another reports on public support for state laws requiring addiction programs to offer FDA-approved medications for opioid use disorder, a finding with direct relevance to ongoing policy debates about whether treatment programs should be legally obligated to provide evidence-based pharmacotherapy. Together, these papers illustrate how service-level research complements clinical neuroscience by identifying where the system itself becomes a barrier to care.

The American Journal of Psychotherapy contributes a third perspective, centered on the human relationship at the heart of psychiatric treatment. Articles examine gender and age differences in psychotherapy use among U.S. adults with depression and anxiety, and explore the effects of psychotherapies for posttraumatic stress disorder on anger, an often-overlooked symptom in trauma treatment research. Clinical technique is addressed in a paper on the RFP-C triangle of conflict, which considers how attending to countertransference can help clinicians listen more effectively to children with disruptive behaviors. Cultural adaptation is the focus of an article on interpersonal psychotherapy in the Chinese cultural context, while a study of group acceptance and commitment therapy for adolescent anxiety reports on initial acceptability and outcomes of a group format aimed at expanding access for young patients.

Psychiatric Research and Clinical Practice rounds out the collection with translational and real-world studies. A viewpoint article considers fostering social connection, tracing progress and opportunities within the VA and beyond, a topic of growing public health interest given evidence linking isolation to morbidity. A comparative study assesses the risks of pregnancy complications in women prescribed psychostimulants or atomoxetine during pregnancy following pre-pregnancy stimulant use, addressing a population long underrepresented in psychopharmacology research. The journal also publishes a real-world effectiveness and cost-differential analysis of intranasal esketamine versus intramuscular ketamine, two rapid-acting treatments for depression whose relative value outside controlled trials remains a pressing question for clinicians and payers. Finally, a real-world pilot evaluates the collaborative care model for adults with cognitive impairment and neuropsychiatric symptoms in primary care, testing whether an integrated care framework developed for depression can extend to patients with complex neuropsychiatric needs. Journalists seeking access to the publications can contact the American Psychiatric Association press office at press@psych.org.

Subject of Research: Neuromodulation, precision therapeutics, esketamine, and mental health services research featured across APA journals

Article Title: October 2026 Issues of APA Journals feature new research on neuromodulation and precision therapeutics, esketamine, and more

Article References: October 2026 Issues of APA Journals feature new research on neuromodulation and precision therapeutics, esketamine, and more. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: neuromodulation, precision therapeutics, brain stimulation, esketamine, theta-burst stimulation, vagus nerve stimulation, electroconvulsive therapy, depression, psychotherapy, psychiatric services, American Psychiatric Association, mental health care